Head & Neck Cancer Drugs Market by Drug Class (Chemotherapy, Immunotherapy, and Targeted Therapy) and Sales Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Stores): Global Opportunity Analysis and Industry Forecast, 2018 - 2025
Head & Neck Cancer Drugs Market Overview:
The global head & neck cancer drugs market was valued at $1,295 million in 2017, and is projected to reach $2,281 million by 2025, registering a CAGR of 7.3% from 2018 to 2025.
Head & neck cancers include a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses, lips, salivary glands and mouth. Head and neck squamous cell carcinoma (HNSCC) is the most common form of head & neck cancer, which develops in the mucous membranes of the mouth, nose, and throat. Chemotherapy, immunotherapy & targeted therapy are used for the treatment of head & neck cancer along with the radiation & surgical procedures.
There is an increase in the demand for head & neck cancer drugs owing to the growth in incidence of head & neck cancer, rise in demand for combination therapeutics, higher number of R&D studies, and surge in adoption of immune therapeutics. In addition, growth in the geriatric population and technological advancements in screening & diagnosis of head & neck cancer further drive the market growth. Strong presence of late-stage pipeline drugs such as Ipilimumab, Atezolizumab, Avelumab, Durvalumab, Erlotinib, Afatinib, Bevacizumab, and others are expected to drive the market growth. However, higher cost & adverse effect associated with head & neck cancer drugs are projected to impede the market growth.
The global head & neck cancer drugs market is segmented based on drug class, sales channel, and region. Based on drug class, the market is classified as chemotherapy, immunotherapy, and targeted therapy. According to the sales channel, the market is categorized as hospital pharmacies, drug stores and retail pharmacies, and online stores. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, and rest of LAMEA).
Key Benefits for Head & Neck Cancer Drugs Market:
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
Head & Neck Cancer Drugs Key Market Segments:
By Drug Class
Chemotherapy
Immunotherapy
Targeted Therapy
By Sales Channel
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Stores
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
List of Key Players Profiled in the Report:
AstraZeneca PLC
Bristol-Myers Squibb Company
Eli Lilly and Company (ARMO Biosciences.)
Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.)
F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
Immutep Limited
Merck & Co., Inc.
Merck KGaA (EMD Serono, Inc.)
Novartis AG
Pfizer Inc.
List of Other Players in the Value Chain (These players are not profiled in the report. The same will be included on request.)
Boehringer Ingelheim
AVEO Pharmaceuticals
The global head & neck cancer drugs market was valued at $1,295 million in 2017, and is projected to reach $2,281 million by 2025, registering a CAGR of 7.3% from 2018 to 2025.
Head & neck cancers include a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses, lips, salivary glands and mouth. Head and neck squamous cell carcinoma (HNSCC) is the most common form of head & neck cancer, which develops in the mucous membranes of the mouth, nose, and throat. Chemotherapy, immunotherapy & targeted therapy are used for the treatment of head & neck cancer along with the radiation & surgical procedures.
There is an increase in the demand for head & neck cancer drugs owing to the growth in incidence of head & neck cancer, rise in demand for combination therapeutics, higher number of R&D studies, and surge in adoption of immune therapeutics. In addition, growth in the geriatric population and technological advancements in screening & diagnosis of head & neck cancer further drive the market growth. Strong presence of late-stage pipeline drugs such as Ipilimumab, Atezolizumab, Avelumab, Durvalumab, Erlotinib, Afatinib, Bevacizumab, and others are expected to drive the market growth. However, higher cost & adverse effect associated with head & neck cancer drugs are projected to impede the market growth.
The global head & neck cancer drugs market is segmented based on drug class, sales channel, and region. Based on drug class, the market is classified as chemotherapy, immunotherapy, and targeted therapy. According to the sales channel, the market is categorized as hospital pharmacies, drug stores and retail pharmacies, and online stores. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, and rest of LAMEA).
Key Benefits for Head & Neck Cancer Drugs Market:
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
Head & Neck Cancer Drugs Key Market Segments:
By Drug Class
Chemotherapy
Immunotherapy
Targeted Therapy
By Sales Channel
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Stores
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
List of Key Players Profiled in the Report:
AstraZeneca PLC
Bristol-Myers Squibb Company
Eli Lilly and Company (ARMO Biosciences.)
Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.)
F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
Immutep Limited
Merck & Co., Inc.
Merck KGaA (EMD Serono, Inc.)
Novartis AG
Pfizer Inc.
List of Other Players in the Value Chain (These players are not profiled in the report. The same will be included on request.)
Boehringer Ingelheim
AVEO Pharmaceuticals
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top player positioning
3.3. MARKET DYNAMICS
3.3.1. Drivers
3.3.1.1. Surge in incidence of head and neck cancer worldwide
3.3.1.2. Surge in global geriatric population
3.3.1.3. Increase in consumption of tobacco and alcohol
3.3.2. Restraints
3.3.2.1. Adverse effects associated with the use of head and neck cancer drugs
3.3.3. Opportunities
3.3.3.1. Untapped emerging economies
3.3.3.2. Increase in number of pipeline drugs
3.3.4. Impact Analyses
CHAPTER 4: HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Chemotherapy
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Immunotherapy
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Targeted therapy
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
CHAPTER 5: HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospital pharmacy
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Online providers
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Drug stores & retail pharmacies
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
CHAPTER 6: HEAD & NECK CANCER DRUGS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. head & neck cancer drugs market, by drug class
6.2.2.1.2. U.S. head & neck cancer drugs market, by sales channel
6.2.2.2. Canada
6.2.2.2.1. Canada head & neck cancer drugs market, by drug class
6.2.2.2.2. Canada head & neck cancer drugs market, by sales channel
6.2.2.3. Mexico
6.2.2.3.1. Mexico head & neck cancer drugs market, by drug class
6.2.2.3.2. Mexico head & neck cancer drugs market, by sales channel
6.2.3. North America market size and forecast, by drug class
6.2.4. North America market size and forecast, by sales channel
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe market size and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Germany head & neck cancer drugs market, by drug class
6.3.2.1.2. Germany head & neck cancer drugs market, by sales channel
6.3.2.2. France
6.3.2.2.1. France head & neck cancer drugs market, by drug class
6.3.2.2.2. France head & neck cancer drugs market, by sales channel
6.3.2.3. UK
6.3.2.3.1. UK head & neck cancer drugs market, by drug class
6.3.2.3.2. UK head & neck cancer drugs market, by sales channel
6.3.2.4. Italy
6.3.2.4.1. Italy head & neck cancer drugs market, by drug class
6.3.2.4.2. Italy head & neck cancer drugs market, by sales channel
6.3.2.5. Spain
6.3.2.5.1. Spain head & neck cancer drugs market, by drug class
6.3.2.5.2. Spain head & neck cancer drugs market, by sales channel
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe head & neck cancer drugs market, by drug class
6.3.2.6.2. Rest of Europe head & neck cancer drugs market, by sales channel
6.3.3. Europe market size and forecast, by drug class
6.3.4. Europe market size and forecast, by sales channel
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan head & neck cancer drugs market, by drug class
6.4.2.1.2. Japan head & neck cancer drugs market, by sales channel
6.4.2.2. China
6.4.2.2.1. China head & neck cancer drugs market, by drug class
6.4.2.2.2. China head & neck cancer drugs market, by sales channel
6.4.2.3. Australia
6.4.2.3.1. Australia head & neck cancer drugs market, by drug class
6.4.2.3.2. Australia head & neck cancer drugs market, by sales channel
6.4.2.4. India
6.4.2.4.1. India head & neck cancer drugs market, by drug class
6.4.2.4.2. India head & neck cancer drugs market, by sales channel
6.4.2.5. South Korea
6.4.2.5.1. South Korea head & neck cancer drugs market, by drug class
6.4.2.5.2. South Korea head & neck cancer drugs market, by sales channel
6.4.2.6. Rest of Asia-Pacific
6.4.2.6.1. Rest of Asia-Pacific head & neck cancer drugs market, by drug class
6.4.2.6.2. Rest of Asia-Pacific head & neck cancer drugs market, by sales channel
6.4.3. Asia-Pacific market size and forecast, by type
6.4.4. Asia-Pacific market size and forecast, by sales channel
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA market size and forecast, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil head & neck cancer drugs market, by drug class
6.5.2.1.2. Brazil head & neck cancer drugs market, by sales channel
6.5.2.2. Saudi Arabia
6.5.2.2.1. Saudi Arabia head & neck cancer drugs market, by drug class
6.5.2.2.2. Saudi Arabia head & neck cancer drugs market, by sales channel
6.5.2.3. South Africa
6.5.2.3.1. South Africa head & neck cancer drugs market, by drug class
6.5.2.3.2. South Africa head & neck cancer drugs market, by sales channel
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA head & neck cancer drugs market, by drug class
6.5.2.4.2. Rest of LAMEA head & neck cancer drugs market, by sales channel
6.5.3. LAMEA market size and forecast, by type
6.5.4. LAMEA market size and forecast, by sales channel
CHAPTER 7: COMPANY PROFILES
7.1. AstraZeneca Plc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product Portfolio
7.1.5. Business performance
7.2. Bristol-Myers Squibb Company
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. Eli Lilly and Company
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product Portfolio
7.3.5. Business performance
7.4. F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. Fresenius Medical Care AG & Co. KGaA
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product Portfolio
7.5.5. Business performance
7.6. Merck & Co., Inc.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product Portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. Pfizer Inc.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product Portfolio
7.7.5. Business performance
7.8. Sanofi
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product Portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Sun Pharmaceutical Industries Ltd.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance
7.10. Teva Pharmaceutical Industries Limited
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product Portfolio
7.10.5. Business performance
7.10.6.Key strategic moves and developments
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top player positioning
3.3. MARKET DYNAMICS
3.3.1. Drivers
3.3.1.1. Surge in incidence of head and neck cancer worldwide
3.3.1.2. Surge in global geriatric population
3.3.1.3. Increase in consumption of tobacco and alcohol
3.3.2. Restraints
3.3.2.1. Adverse effects associated with the use of head and neck cancer drugs
3.3.3. Opportunities
3.3.3.1. Untapped emerging economies
3.3.3.2. Increase in number of pipeline drugs
3.3.4. Impact Analyses
CHAPTER 4: HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Chemotherapy
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Immunotherapy
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Targeted therapy
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
CHAPTER 5: HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospital pharmacy
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Online providers
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Drug stores & retail pharmacies
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
CHAPTER 6: HEAD & NECK CANCER DRUGS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. head & neck cancer drugs market, by drug class
6.2.2.1.2. U.S. head & neck cancer drugs market, by sales channel
6.2.2.2. Canada
6.2.2.2.1. Canada head & neck cancer drugs market, by drug class
6.2.2.2.2. Canada head & neck cancer drugs market, by sales channel
6.2.2.3. Mexico
6.2.2.3.1. Mexico head & neck cancer drugs market, by drug class
6.2.2.3.2. Mexico head & neck cancer drugs market, by sales channel
6.2.3. North America market size and forecast, by drug class
6.2.4. North America market size and forecast, by sales channel
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe market size and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Germany head & neck cancer drugs market, by drug class
6.3.2.1.2. Germany head & neck cancer drugs market, by sales channel
6.3.2.2. France
6.3.2.2.1. France head & neck cancer drugs market, by drug class
6.3.2.2.2. France head & neck cancer drugs market, by sales channel
6.3.2.3. UK
6.3.2.3.1. UK head & neck cancer drugs market, by drug class
6.3.2.3.2. UK head & neck cancer drugs market, by sales channel
6.3.2.4. Italy
6.3.2.4.1. Italy head & neck cancer drugs market, by drug class
6.3.2.4.2. Italy head & neck cancer drugs market, by sales channel
6.3.2.5. Spain
6.3.2.5.1. Spain head & neck cancer drugs market, by drug class
6.3.2.5.2. Spain head & neck cancer drugs market, by sales channel
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe head & neck cancer drugs market, by drug class
6.3.2.6.2. Rest of Europe head & neck cancer drugs market, by sales channel
6.3.3. Europe market size and forecast, by drug class
6.3.4. Europe market size and forecast, by sales channel
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan head & neck cancer drugs market, by drug class
6.4.2.1.2. Japan head & neck cancer drugs market, by sales channel
6.4.2.2. China
6.4.2.2.1. China head & neck cancer drugs market, by drug class
6.4.2.2.2. China head & neck cancer drugs market, by sales channel
6.4.2.3. Australia
6.4.2.3.1. Australia head & neck cancer drugs market, by drug class
6.4.2.3.2. Australia head & neck cancer drugs market, by sales channel
6.4.2.4. India
6.4.2.4.1. India head & neck cancer drugs market, by drug class
6.4.2.4.2. India head & neck cancer drugs market, by sales channel
6.4.2.5. South Korea
6.4.2.5.1. South Korea head & neck cancer drugs market, by drug class
6.4.2.5.2. South Korea head & neck cancer drugs market, by sales channel
6.4.2.6. Rest of Asia-Pacific
6.4.2.6.1. Rest of Asia-Pacific head & neck cancer drugs market, by drug class
6.4.2.6.2. Rest of Asia-Pacific head & neck cancer drugs market, by sales channel
6.4.3. Asia-Pacific market size and forecast, by type
6.4.4. Asia-Pacific market size and forecast, by sales channel
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA market size and forecast, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil head & neck cancer drugs market, by drug class
6.5.2.1.2. Brazil head & neck cancer drugs market, by sales channel
6.5.2.2. Saudi Arabia
6.5.2.2.1. Saudi Arabia head & neck cancer drugs market, by drug class
6.5.2.2.2. Saudi Arabia head & neck cancer drugs market, by sales channel
6.5.2.3. South Africa
6.5.2.3.1. South Africa head & neck cancer drugs market, by drug class
6.5.2.3.2. South Africa head & neck cancer drugs market, by sales channel
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA head & neck cancer drugs market, by drug class
6.5.2.4.2. Rest of LAMEA head & neck cancer drugs market, by sales channel
6.5.3. LAMEA market size and forecast, by type
6.5.4. LAMEA market size and forecast, by sales channel
CHAPTER 7: COMPANY PROFILES
7.1. AstraZeneca Plc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product Portfolio
7.1.5. Business performance
7.2. Bristol-Myers Squibb Company
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. Eli Lilly and Company
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product Portfolio
7.3.5. Business performance
7.4. F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. Fresenius Medical Care AG & Co. KGaA
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product Portfolio
7.5.5. Business performance
7.6. Merck & Co., Inc.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product Portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. Pfizer Inc.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product Portfolio
7.7.5. Business performance
7.8. Sanofi
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product Portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Sun Pharmaceutical Industries Ltd.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance
7.10. Teva Pharmaceutical Industries Limited
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product Portfolio
7.10.5. Business performance
7.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 02. CHEMOTHERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 20172025 ($MILLION)
TABLE 03. IMMUNOTHERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 20172025 ($MILLION)
TABLE 04. TARGETED THERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 20172025 ($MILLION)
TABLE 05. GLOBAL HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 06. HEAD & NECK CANCER DRUGS MARKET FOR HOSPITAL PHARMACY, BY REGION, 20172025 ($MILLION)
TABLE 07. HEAD & NECK CANCER DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 20172025 ($MILLION)
TABLE 08. HEAD & NECK CANCER DRUGS MARKET FOR DRUG STORES & RETAIL PHARMACIES, BY REGION, 20172025 ($MILLION)
TABLE 09. HEAD & NECK CANCER DRUGS MARKET REVENUE, BY REGION, 20172025 ($MILLION)
TABLE 10. NORTH AMERICA HEAD & NECK CANCER DRUGS MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 11. U.S. HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 12. U.S. HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 13. CANADA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 14. CANADA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 15. MEXICO HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 16. MEXICO HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 17. NORTH AMERICA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 18. NORTH AMERICA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 19. EUROPE HEAD & NECK CANCER DRUGS MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 20. GERMANY HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 21. GERMANY HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 22. FRANCE HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 23. FRANCE HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 24. UK HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 25. UK HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 26. ITALY HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 27. ITALY HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 28. SPAIN HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 29. SPAIN HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 30. REST OF EUROPE HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 31. REST OF EUROPE HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 32. EUROPE HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 33. EUROPE HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 34. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 35. JAPAN HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 36. JAPAN HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 37. CHINA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 38. CHINA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 39. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 40. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 41. INDIA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 42. INDIA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 43. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 44. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 45. REST OF ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 46. REST OF ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 47. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 48. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 49. LAMEA HEAD & NECK CANCER DRUGS MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 50. BRAZIL HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 51. BRAZIL HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 52. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 53. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 54. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 55. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 56. REST OF LAMEA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 57. REST OF LAMEA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 58. LAMEA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 59. LAMEA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 60. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 61. ASTRAZENECA: OPERATING SEGMENTS
TABLE 62. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 63. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 64. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 65. LILLY: COMPANY SNAPSHOT
TABLE 66. LILLY: OPERATING SEGMENTS
TABLE 67. LILLY: PRODUCT PORTFOLIO
TABLE 68. ROCHE: COMPANY SNAPSHOT
TABLE 69. ROCHE: OPERATING SEGMENTS
TABLE 70. ROCHE: PRODUCT PORTFOLIO
TABLE 71. FRESENIUS MEDICAL CARE: COMPANY SNAPSHOT
TABLE 72. FRESENIUS MEDICAL CARE: OPERATING SEGMENTS
TABLE 73. FRESENIUS MEDICAL CARE: PRODUCT PORTFOLIO
TABLE 74. MERCK: COMPANY SNAPSHOT
TABLE 75. MERCK: OPERATING SEGMENTS
TABLE 76. MERCK: PRODUCT PORTFOLIO
TABLE 77. PFIZER: COMPANY SNAPSHOT
TABLE 78. PFIZER: OPERATING SEGMENTS
TABLE 79. PFIZER: PRODUCT PORTFOLIO
TABLE 80. SANOFI: COMPANY SNAPSHOT
TABLE 81. SANOFI: OPERATING SEGMENTS
TABLE 82. SANOFI: PRODUCT PORTFOLIO
TABLE 83. SUN PHARMA: COMPANY SNAPSHOT
TABLE 84. SUN PHARMA: OPERATING SEGMENTS
TABLE 85. SUN PHARMA: PRODUCT PORTFOLIO
TABLE 86. TEVA: COMPANY SNAPSHOT
TABLE 87. TEVA: OPERATING SEGMENTS
TABLE 88. TEVA: PRODUCT PORTFOLIO
TABLE 01. GLOBAL HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 02. CHEMOTHERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 20172025 ($MILLION)
TABLE 03. IMMUNOTHERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 20172025 ($MILLION)
TABLE 04. TARGETED THERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 20172025 ($MILLION)
TABLE 05. GLOBAL HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 06. HEAD & NECK CANCER DRUGS MARKET FOR HOSPITAL PHARMACY, BY REGION, 20172025 ($MILLION)
TABLE 07. HEAD & NECK CANCER DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 20172025 ($MILLION)
TABLE 08. HEAD & NECK CANCER DRUGS MARKET FOR DRUG STORES & RETAIL PHARMACIES, BY REGION, 20172025 ($MILLION)
TABLE 09. HEAD & NECK CANCER DRUGS MARKET REVENUE, BY REGION, 20172025 ($MILLION)
TABLE 10. NORTH AMERICA HEAD & NECK CANCER DRUGS MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 11. U.S. HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 12. U.S. HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 13. CANADA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 14. CANADA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 15. MEXICO HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 16. MEXICO HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 17. NORTH AMERICA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 18. NORTH AMERICA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 19. EUROPE HEAD & NECK CANCER DRUGS MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 20. GERMANY HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 21. GERMANY HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 22. FRANCE HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 23. FRANCE HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 24. UK HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 25. UK HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 26. ITALY HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 27. ITALY HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 28. SPAIN HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 29. SPAIN HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 30. REST OF EUROPE HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 31. REST OF EUROPE HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 32. EUROPE HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 33. EUROPE HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 34. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 35. JAPAN HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 36. JAPAN HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 37. CHINA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 38. CHINA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 39. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 40. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 41. INDIA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 42. INDIA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 43. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 44. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 45. REST OF ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 46. REST OF ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 47. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 48. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 49. LAMEA HEAD & NECK CANCER DRUGS MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 50. BRAZIL HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 51. BRAZIL HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 52. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 53. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 54. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 55. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 56. REST OF LAMEA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 57. REST OF LAMEA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 58. LAMEA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 ($MILLION)
TABLE 59. LAMEA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 ($MILLION)
TABLE 60. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 61. ASTRAZENECA: OPERATING SEGMENTS
TABLE 62. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 63. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 64. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 65. LILLY: COMPANY SNAPSHOT
TABLE 66. LILLY: OPERATING SEGMENTS
TABLE 67. LILLY: PRODUCT PORTFOLIO
TABLE 68. ROCHE: COMPANY SNAPSHOT
TABLE 69. ROCHE: OPERATING SEGMENTS
TABLE 70. ROCHE: PRODUCT PORTFOLIO
TABLE 71. FRESENIUS MEDICAL CARE: COMPANY SNAPSHOT
TABLE 72. FRESENIUS MEDICAL CARE: OPERATING SEGMENTS
TABLE 73. FRESENIUS MEDICAL CARE: PRODUCT PORTFOLIO
TABLE 74. MERCK: COMPANY SNAPSHOT
TABLE 75. MERCK: OPERATING SEGMENTS
TABLE 76. MERCK: PRODUCT PORTFOLIO
TABLE 77. PFIZER: COMPANY SNAPSHOT
TABLE 78. PFIZER: OPERATING SEGMENTS
TABLE 79. PFIZER: PRODUCT PORTFOLIO
TABLE 80. SANOFI: COMPANY SNAPSHOT
TABLE 81. SANOFI: OPERATING SEGMENTS
TABLE 82. SANOFI: PRODUCT PORTFOLIO
TABLE 83. SUN PHARMA: COMPANY SNAPSHOT
TABLE 84. SUN PHARMA: OPERATING SEGMENTS
TABLE 85. SUN PHARMA: PRODUCT PORTFOLIO
TABLE 86. TEVA: COMPANY SNAPSHOT
TABLE 87. TEVA: OPERATING SEGMENTS
TABLE 88. TEVA: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. HEAD & NECK CANCER DRUGS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS IN THE GLOBAL HEAD & NECK CANCER DRUGS MARKET
FIGURE 03. TOP PLAYER POSITIONING, 2017
FIGURE 04. WORLD POPULATION AGED 65 AND OVER (%)
FIGURE 05. IMPACT ANALYSES, HEAD AND NECK CANCER DRUG MARKET
FIGURE 06. COMPARATIVE COUNTRY ANALYSIS OF CHEMOTHERAPY MARKET FOR HEAD & NECK CANCER, 2017 AND 2025 ($MILLION)
FIGURE 07. COMPARATIVE COUNTRY ANALYSIS OF IMMUNOTHERAPY MARKET FOR HEAD & NECK CANCER, 2017 AND 2025 ($MILLION)
FIGURE 08. COMPARATIVE COUNTRY ANALYSIS OF TARGETED THERAPY MARKET FOR HEAD & NECK CANCER, 2017 AND 2025 ($MILLION)
FIGURE 09. COMPARATIVE COUNTRY ANALYSIS HEAD & NECK CANCER DRUGS MARKET FOR HOSPITAL PHARMACY, 2017 AND 2025 ($MILLION)
FIGURE 10. COMPARATIVE COUNTRY ANALYSIS HEAD & NECK CANCER DRUGS MARKET FOR ONLINE PROVIDERS, 2017 AND 2025 ($MILLION)
FIGURE 11. COMPARATIVE COUNTRY ANALYSIS HEAD & NECK CANCER DRUGS MARKET FOR DRUG STORES & RETAIL PHARMACIES, 2017 AND 2025 ($MILLION)
FIGURE 12. ASTRAZENECA: REVENUE, 20152017 ($MILLION)
FIGURE 13. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 14. REVENUE, 20152017 ($MILLION)
FIGURE 15. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 16. REVENUE, 20152017 ($MILLION)
FIGURE 17. LILLY: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 18. LILLY: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 19. ROCHE: NET SALES, 20152017 ($MILLION)
FIGURE 20. ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 21. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 22. FRESENIUS MEDICAL CARE: NET SALES, 20152017 ($MILLION)
FIGURE 23. FRESENIUS MEDICAL CARE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 24. MERCK: NET SALES, 20152017 ($MILLION)
FIGURE 25. MERCK: NET SALES BY SEGMENT, 2017 (%)
FIGURE 26. MERCK: NET SALES BY GEOGRAPHY, 2017 (%)
FIGURE 27. PFIZER: REVENUE, 20152017 ($MILLION)
FIGURE 28. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 29. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 30. SANOFI: NET SALES, 20152017 ($MILLION)
FIGURE 31. SANOFI: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 32. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 33. SUN PHARMA: NET SALES, 20152017 ($MILLION)
FIGURE 34. SUN PHARMA: NET SALES BY SEGMENT, 2017 (%)
FIGURE 35. TEVA: REVENUE, 20152017 ($MILLION)
FIGURE 36. TEVA: REVENUE BY SEGMENT, 2017 (%)
FIGURE 37. TEVA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 01. HEAD & NECK CANCER DRUGS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS IN THE GLOBAL HEAD & NECK CANCER DRUGS MARKET
FIGURE 03. TOP PLAYER POSITIONING, 2017
FIGURE 04. WORLD POPULATION AGED 65 AND OVER (%)
FIGURE 05. IMPACT ANALYSES, HEAD AND NECK CANCER DRUG MARKET
FIGURE 06. COMPARATIVE COUNTRY ANALYSIS OF CHEMOTHERAPY MARKET FOR HEAD & NECK CANCER, 2017 AND 2025 ($MILLION)
FIGURE 07. COMPARATIVE COUNTRY ANALYSIS OF IMMUNOTHERAPY MARKET FOR HEAD & NECK CANCER, 2017 AND 2025 ($MILLION)
FIGURE 08. COMPARATIVE COUNTRY ANALYSIS OF TARGETED THERAPY MARKET FOR HEAD & NECK CANCER, 2017 AND 2025 ($MILLION)
FIGURE 09. COMPARATIVE COUNTRY ANALYSIS HEAD & NECK CANCER DRUGS MARKET FOR HOSPITAL PHARMACY, 2017 AND 2025 ($MILLION)
FIGURE 10. COMPARATIVE COUNTRY ANALYSIS HEAD & NECK CANCER DRUGS MARKET FOR ONLINE PROVIDERS, 2017 AND 2025 ($MILLION)
FIGURE 11. COMPARATIVE COUNTRY ANALYSIS HEAD & NECK CANCER DRUGS MARKET FOR DRUG STORES & RETAIL PHARMACIES, 2017 AND 2025 ($MILLION)
FIGURE 12. ASTRAZENECA: REVENUE, 20152017 ($MILLION)
FIGURE 13. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 14. REVENUE, 20152017 ($MILLION)
FIGURE 15. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 16. REVENUE, 20152017 ($MILLION)
FIGURE 17. LILLY: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 18. LILLY: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 19. ROCHE: NET SALES, 20152017 ($MILLION)
FIGURE 20. ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 21. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 22. FRESENIUS MEDICAL CARE: NET SALES, 20152017 ($MILLION)
FIGURE 23. FRESENIUS MEDICAL CARE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 24. MERCK: NET SALES, 20152017 ($MILLION)
FIGURE 25. MERCK: NET SALES BY SEGMENT, 2017 (%)
FIGURE 26. MERCK: NET SALES BY GEOGRAPHY, 2017 (%)
FIGURE 27. PFIZER: REVENUE, 20152017 ($MILLION)
FIGURE 28. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 29. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 30. SANOFI: NET SALES, 20152017 ($MILLION)
FIGURE 31. SANOFI: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 32. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 33. SUN PHARMA: NET SALES, 20152017 ($MILLION)
FIGURE 34. SUN PHARMA: NET SALES BY SEGMENT, 2017 (%)
FIGURE 35. TEVA: REVENUE, 20152017 ($MILLION)
FIGURE 36. TEVA: REVENUE BY SEGMENT, 2017 (%)
FIGURE 37. TEVA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
